Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
View Patent ↗Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.
1. A method of treating ischemic optic neuropathy in an eye of a person in need thereof, the method comprising administering, to the person, a composition comprising a therapeutically effective amount of nutlin-3 or nutlin-3a.
2. The method of claim 1 , wherein the composition is administered to said person once to four times per day.
3. The method of claim 1 , wherein the composition is administered once per week.
4. The method of claim 1 , wherein the composition is administered once.
5. The method of claim 1 , wherein the composition is formulated for intravitreal injection or topical delivery.
6. The method of claim 5 , wherein the composition is formulated for intravitreal injection.
7. The method of claim 1 , wherein the composition further comprises a preservative.
8. The method of claim 7 , wherein the preservative is less than 0.005 wt. %.
9. The method of claim 7 , wherein the preservative is benzalkonium chloride.